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Background: Colorectal cancer (CRC) is common and associated with significant mortality. Current screening methods for CRC
lack patient compliance. microRNAs (miRNAs), identified in body fluids, are negative regulators of gene expression and are
dysregulated in many cancers, including CRC. This paper summarises studies identifying blood-based miRNAs dysregulated in
CRC compared with healthy controls in an attempt to evaluate their use as a screening tool for the diagnosis of CRC.
Methods: A search of electronic databases (PubMed and EMBASE) and grey literature was performed between January 2002 and
April 2016. Studies reporting plasma or serum miRNAs in the diagnosis of CRC compared with healthy controls were selected.
Patient demographics, type of patient sample (serum or plasma), method of miRNA detection, type of normalisation, and the
number of significantly dysregulated miRNAs identified were recorded. Statistical evaluation of dysregulated miRNAs using
sensitivity, specificity, and area under the curve (AUC) was performed.
Results: Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included. A total of 31 miRNAs
were found to be either upregulated (n¼ 17) or downregulated (n¼ 14) in CRC cases as compared with controls. Fourteen studies
identified panels of X2 dysregulated miRNAs. The highest AUC, 0.943, was identified using a panel of 4 miRNAs with 83.3%
sensitivity and 93.1% specificity. Meta-analysis of studies identifying a single dysregulated miRNA in CRC cases compared
with controls was performed. Overall sensitivity and specificity of 28 individual miRNAs in the diagnosis of CRC were 76% (95% CI
72%–80%) and 76% (95% CI 72%–80%), respectively, indicating good discriminative ability of miRNAs as biomarkers for CRC.
These data did not change with sensitivity analyses.
Conclusions: Blood-based miRNAs distinguish patients with CRC from healthy controls with high sensitivity and specificity
comparable to other common and invasive currently used screening methods for CRC. In future, miRNAs may be used as a
relatively non-invasive blood-based marker for detection of CRC.
Colorectal cancer (CRC) is a common cancer with substantial
mortality. A significant proportion of CRC arises from preexisting
colorectal adenomas (CAA; polyps) through the adenoma–
carcinoma sequence. In this sequence, a stepwise pattern of genetic
changes drive normal colonic epithelium to invasive cancer. Many
deaths could be avoided if precancerous adenomas or early-stage
cancers could be identified and treated prior to the development of
more advanced malignancy (Muller and Sonnenberg, 1995; Zauber
et al, 2012). Current screening tools for detection of CRC include
colonoscopy, faecal-based tests (occult blood testing and DNA-
based stool tests), and plasma-based assays. As these methods
each have disadvantages, including morbidity (Lohsiriwat, 2010),
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low sensitivity and specificity (Hundt et al, 2009), expense
(Calderwood and Jacobson, 2013), and poor patient compliance
(Logan et al, 2012), there is need for a more accurate, less invasive
screening tool to permit early detection and intervention.
Biological markers or biomarkers are defined as ‘a characteristic
that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmaco-
logical responses to a therapeutic intervention’ (Naylor, 2003).
Biomarkers, such as blood, urine, and cerebrospinal fluid, can be
used for screening, diagnosis, and predicting prognosis in human
diseases (Mayeux, 2004). Plasma and serum are components of
blood and are commonly used in diagnostic assays. Serum is of
similar composition to plasma except for lacking clotting factors.
Both plasma and serum contain hormones, glucose, electrolytes,
antibodies, antigens, and nutrients making them ideal media in
diagnostic testing (Maton et al, 1993). The most commonly used
blood-based CRC biomarker, carcinoembryonic antigen, which is
used for postoperative surveillance and for monitoring response to
therapy, lacks sensitivity and specificity for screening or for the
detection of recurrent CRC (Fakih and Padmanabhan, 2006).
microRNAs (miRNAs) are small, non-protein-coding RNA
molecules that regulate gene expression by complementary binding
to the 30 untranslated region of target mRNA. They cause target
degradation, translational repression, or gene silencing and thus
affect subsequent protein expression. miRNAs exhibit important
regulatory functions related to cell differentiation, development,
and growth (Meltzer, 2005; Croce, 2008). They have also been
shown to be dysregulated in a number of cancers, including CRC,
by influencing oncogenes and tumour-suppressor genes (Zhang
et al, 2007; Chiang et al, 2012). miRNAs have been identified in
body fluids, such as plasma, saliva, urine, and faeces (Chevillet
et al, 2014). They have been shown to be actively released from
cells in microvesicles, exosomes, or bound to proteins. miRNAs are
inherently stable accounting for the emerging use as potential
biomarkers for human disease and as targets for disease
intervention (Kanaan et al, 2012; Mishra, 2014).
The purpose of this systematic review and meta-analysis is to
assess published studies describing the use of plasma- or serum-
based miRNAs as biomarkers for the diagnosis of CRC, to assess
the accuracy of these miRNAs as biomarkers, and to identify those
miRNAs for which there is the most evidence of potential use as a
specific and sensitive blood-based assay for the diagnosis of CRC.
MATERIALS AND METHODS
This study was conducted according to the Preferred Reporting
Items for Systematic Reviews and Meta-analysis guidelines (Mahid
et al, 2006; Moher et al, 2009). Two reviewers (JC, NG) were
independently involved with study selection, data extraction, and
quality assessment.
Study selection. An electronic search of PubMed (NCBI,
Bethesda, MD, USA) and EMBASE (Elsevier, Amsterdam, The
Netherlands) databases was performed for relevant articles
published between January 2002 and April 2016 using the
following medical subject heading terms: (‘plasma’ OR ‘serum’)
AND (‘microRNA’ OR ‘miRNAs’ OR ‘miR*’) AND (‘colorectal
cancer’ OR ‘colorectal carcinoma’ OR ‘colon cancer’ OR ‘colorectal
adenoma’). This time period was based on a preliminary search
that revealed no serum or plasma miRNA studies in patients with
CRC undertaken prior to 2002. A grey literature search of meeting
proceedings and abstracts was performed to detect any relevant
unpublished work (Mahid et al, 2006). Meeting proceedings from
the following organisations were searched for abstracts relevant to
plasma miRNA and CRC for the period 2010 and 2016: American
Society for Clinical Oncology, the American Society of Colon and
Rectal Surgeons, the American Association for Cancer Research,
and the Society for Surgical Oncology.
No language restrictions were imposed. Duplicates were
removed. Based on the title and abstract, manuscripts of interest
were obtained for full-text review. Only full-text manuscripts were
included. Additional articles were identified by manually searching
the references of original and review articles.
Inclusion and exclusion criteria. Inclusion and exclusion criteria
were developed by the investigative team. Human studies
investigating plasma- or serum-based miRNAs as a method for
diagnosis of CRC using patients with CRC as compared with
healthy controls were included. Studies evaluating treatment
response were excluded, as were studies evaluating tissue miRNA
or miRNA in other body fluids. The primary outcome measure was
determination of significantly dysregulated serum or plasma
miRNA in patients with CRC as compared with healthy controls.
Data extraction, meta-analysis, and quality assessment. Each
manuscript was assessed independently by two investigators (JC
and NG). Disagreements among reviewers were resolved by
consensus. Data extracted included the following: authors,
publication year, country, type of blood-based fluid (serum or
plasma), characteristics of the study population (both case and
control), study design (qRT-PCR detection method), whether
miRNA screening was performed, number of miRNAs assessed,
listing of the specific dysregulated miRNAs in patients with CRC as
compared with controls, and outcome of statistical analyses
including details of miRNA analysis, such as type of reference
miRNA utilised. Studies reporting on single miRNA were included
in the meta-analysis and were evaluated according to the Quality
Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)
checklist (Whiting et al, 2011). QUADAS-2 is designed to assess
the risk of bias and applicability of studies of diagnostic accuracy. It
consists of four domains: patient selection, index test, reference
standard, and flow and timing. Each is assessed with respect to the
risk of bias and the first three domains assessed with respect to
applicability.
Statistical analysis. Analysis was based on the accuracy of the
identified miRNAs to diagnose the presence of CRC as determined
using Receiver Operator Characteristic (ROC) curves as Area
Under the Curve (AUC) value and sensitivity and specificity, where
available (Carter et al, 2016a). Studies that identified the sensitivity
and specificity of individual miRNA in diagnosing CRC were
included in the meta-analysis. Owing to the presumed hetero-
geneity of studies, a random-effects model (DerSimonian–Laird
method) was used (Mahid et al, 2006). Forest plots were
constructed using STATA version 11 (StataCorp LP, College,
Station, TX, USA). The heterogeneity of included studies was
assessed using I2 and w2 statistics and was judged to be significant if
I2 was 450% or Po0.05. Sensitivity analyses were performed for
(1) studies judged to have low risk and low concern following
QUADAS-2 assessment (see above), (2) based upon the type of
sample used (i.e., plasma or serum), (3) the method of qRT-PCR
detection (TaqMan or SYBR Green), and (4) the type of reference
control used for normalisation (internal or external).
RESULTS
Three hundred and ninety-nine records from the database search
and 3 from the grey literature were initially identified (Figure 1);
282 records remained after duplicates were removed and a further
190 were considered not relevant to the review topic. Ninety-two
records were screened, and after abstract review, 33 were
subsequently excluded owing to a lack of reporting on miRNA,
results using cancers other than CRC, non-human subjects, and/or
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inability to obtain full abstracts or articles. Full-text articles were
obtained for the remaining 59 articles that were deemed relevant.
A further 25 articles were excluded for the following reasons:
review article (n¼ 14), abstract only (n¼ 2), not plasma or serum
(n¼ 1), not diagnostic (n¼ 5), and not CRC (n¼ 3). Thirty-four
studies investigating plasma or serum miRNAs in the diagnosis of
CRC were included for the final systematic review (Ng et al, 2009;
Huang et al, 2010; Pu et al, 2010; Ahmed et al, 2012; Kanaan et al,
2012; Wang and Zhang, 2012; Wang et al, 2012b; Brunet Vega
et al, 2013; Giraldez et al, 2013; Hofsli et al, 2013; Kanaan et al,
2013; Liu et al, 2013; Luo et al, 2013; Toiyama et al, 2013; Yu et al,
2013; Zhang et al, 2013; Basati et al, 2014; Du et al, 2014; Perilli
et al, 2014; Xu et al, 2014; Zanutto et al, 2014; Zheng et al, 2014;
Basati et al, 2015; Chen et al, 2015; Fang et al, 2015; Ghanbari et al,
2015; Ho et al, 2015; Ramzy et al, 2015; Wang et al, 2015; Li et al,
2015; Li et al, 2016; Sun et al, 2016; Wang et al, 2016; Yu et al,
2016) and of these 19 were included in the meta-analysis (Ng et al,
2009; Huang et al, 2010; Pu et al, 2010; Kanaan et al, 2012; Wang
and Zhang, 2012; Wang et al, 2012b; Liu et al, 2013; Toiyama et al,
2013; Zhang et al, 2013; Basati et al, 2014; Du et al, 2014; Xu et al,
2014; Basati et al, 2015; Chen et al, 2015; Fang et al, 2015; Li et al,
2016; Sun et al, 2016; Wang et al, 2016; Yu et al, 2016). Of these 34
studies, 20 (59%) used plasma (Ng et al, 2009; Huang et al, 2010;
Pu et al, 2010; Ahmed et al, 2012; Kanaan et al, 2012; Wang et al,
2012b; Giraldez et al, 2013; Kanaan et al, 2013; Luo et al, 2013;
Zhang et al, 2013; Du et al, 2014; Perilli et al, 2014; Xu et al, 2014;
Zanutto et al, 2014; Chen et al, 2015; Fang et al, 2015; Ghanbari
et al, 2015; Wang et al, 2015; Li et al, 2016; Sun et al, 2016) and 14
(41%) used serum samples (Wang and Zhang, 2012; Brunet Vega
et al, 2013; Hofsli et al, 2013; Liu et al, 2013; Toiyama et al, 2013;
Yu et al, 2013; Basati et al, 2014; Zheng et al, 2014; Basati et al,
2015; Ho et al, 2015; Ramzy et al, 2015; Li et al, 2015; Wang et al,
2016; Yu et al, 2016). Studies were conducted in North America,
South East Asia, or Europe. Study characteristics are shown in
Table 1.
A total of 6010 patients were included; 3454 CRC patients, and
2556 healthy controls. Seven studies also included evaluation of
420 patients with CAA, the precursor lesion to CRC. From the
studies that reported patient demographics, 1792 men and 1410
women were included among CRC cases and 1198 men and 942
women were included among healthy controls (Table 1).
All patients included in this review had the diagnosis of CRC
confirmed by histopathology. Patients were excluded from
individual studies if they had a diagnosis of familial adenomatous
polyposis, hereditary non-polyposis CRC or other inflammatory
condition or if they received preoperative radiotherapy or
chemotherapy. Of the 19 studies included in meta-analysis, 18
studies staged CRC according to either the American Joint
Committee on Cancer or the Union for International Cancer
Control Tumor-Node-Metastasis staging system. The remaining
study staged CRC cases according to the Dukes’ classification
system.
Identification of dysregulated miRNAs in the plasma or
serum. Sixteen of the 34 studies performed miRNA screening
studies (Ng et al, 2009; Ahmed et al, 2012; Kanaan et al, 2012;
Wang et al, 2012b; Brunet Vega et al, 2013; Giraldez et al, 2013;
Hofsli et al, 2013; Kanaan et al, 2013; Luo et al, 2013; Zheng et al,
2014; Xu et al, 2014; Ghanbari et al, 2015; Ho et al, 2015; Wang
et al, 2015; Li et al, 2015; Sun et al, 2016) in order to identify
dysregulated miRNAs in the plasma or serum of CRC cases
compared with healthy controls, whereas the remaining 18 studies
identified miRNAs for assessment based on the literature or based
on their own prior studies (Huang et al, 2010; Pu et al, 2010; Wang
and Zhang, 2012; Liu et al, 2013; Yu et al, 2013; Toiyama et al,
2013; Zhang et al, 2013; Basati et al, 2014; Du et al, 2014; Perilli
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Figure 1. Flow diagram of the literature search process and study inclusion.
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Table 1. Characteristics of studies included in systematic review
Study population











Ng 2009 China 130 75 CRC 71 (42–91) 68 : 62 Plasma
Control 69 (45–85) 39 : 36
Huang 2010 China 100 59 CRC 61±11 51 : 49 Plasma
Control 58±12 31 : 28
Pu 2010 China 103 37 CRC 58 (39–84) 66 : 37 Plasma
Control 32 (17–77) 19 : 18
Kanaan 2012 USA 50 50 CRC 60±11 21 : 29 Plasma
Control 61±9 21 : 29
Wang Q 2012 China 100 68 CRC 61 (21–84) 50 : 50 Plasma
Control 57 (36–85) 35 : 33
Wang B 2012 China 32 39 CRC 63 (45–80) 17 : 15 Serum
Control 46 30 : 9
Ahmed 2012 USA 10 5 CRC — — Plasma
Control — —
Kanaan 2013 USA 45 26 CRC 64 28 : 17 Plasma
Control 60±11 11 : 15
Zhang G 2012 China 78 86 CRC 61.4±13.6 43 : 35 Plasma
Control 60.3±11.8 53 : 33
Luo 2013 Germany 130 244 CRC 67.55 70 : 60 Plasma
Control 61.93 105 : 139
Giraldez 2013 Spain 63 73 CRC — — Plasma
Control 61.35 37 : 36
Brunet Vega 2013 Spain 30 26 CRC 68.1±11 18 : 12 Serum
Control 64.1±7.4 13 : 13
Liu 2013 China 200 80 CRC 57.09 (20–89) 126 : : 74 Serum
Control 57.71 (28–89) 42 : 38
Yu H 2013 China 30 30 CRC — — Serum
Control — —
Toiyama 2013 USA 186 53 CRC 67.5±7.5 106 : 80 Serum
Control 64±12.9 27 : 26
Hofsli 2013 Norway 70 20 CRC 70.5 32 : 38 Serum
Control X50 10 : 10
Perilli 2014 Italy 20 10 CRC — — Plasma
Control — —
Basati 2014 Iran 40 40 CRC 55.35±10.13 21 : 19 Serum
Control 55.00±10.35 22 : 18
Zheng 2014 China 307 226 CRC 57.68 180 : 127 Serum
Control 53.15 128 : 98
Du 2014 China 49 49 CRC — — Plasma
Control — —
Xu 2014 China 94 46 CRC 64.9 54 : 40 Plasma
Control 65.8 22 : 24
Zanutto 2014 Italy 65 70 CRC — — Plasma
Control — —
Chen 2015 China 100 79 CRC 58.91 60 : 40 Plasma
Control 60.20 44 : 35
Ramzy 2015 Egypt 25 10 CRC — — Serum
Control — —
Ho 2015 USA 11 10 CRC 68.0 8 : 3 Serum
Control 54.5 4 : 6
Li J 2015 China 175 130 CRC 58.7 113 : 62 Serum
Control 54.1 70 : 50
Li L 2015 China 200 400 CRC 66.3±11.8 135 : 65 Plasma
Control 65.5±10.8 283 : : 117
Fang 2015 China 111 130 CRC 60 59 : 52 Plasma
Control — —
Basati 2015 Iran 55 55 CRC 58.52±10 30 : 25 Serum
Control 57.87±10.15 31 : 24
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et al, 2014; Zanutto et al, 2014; Basati et al, 2015; Chen et al, 2015;
Fang et al, 2015; Ramzy et al, 2015; Li et al, 2016; Wang et al, 2016;
Yu et al, 2016). A total of 617 miRNAs were differentially
expressed between CRC and healthy controls in these screening
studies, and of these, 69 miRNAs were found to be significantly
dysregulated in validation or subsequent studies. A further 36
miRNAs were shown to have either increased or decreased
expression in CRC, but no statistical analyses were performed
(Ahmed et al, 2012; Hofsli et al, 2013) (Supplementary Table S1).
Significantly dysregulated miRNAs in the plasma or serum of
CRC cases. Thirty-one miRNAs were found to be either
upregulated (n¼ 17, miR-17-3p, miR-18a, miR-19a-3p, miR-20a,
miR-21, miR-29a, miR-92, miR-96, miR-106a, miR-182, miR-200c,
miR-206, miR-210, miR-221, miR-223-3p, miR-372, miR-378)
(Ng et al, 2009; Huang et al, 2010; Pu et al, 2010; Kanaan et al,
2012; Wang and Zhang, 2012; Brunet Vega et al, 2013; Liu et al,
2013; Toiyama et al, 2013; Zhang et al, 2013; Basati et al, 2014; Du
et al, 2014; Perilli et al, 2014; Xu et al, 2014; Zanutto et al, 2014;
Zheng et al, 2014; Chen et al, 2015; Yamada et al, 2015; Li et al,
2015; Sun et al, 2016; Wang et al, 2016; Yu et al, 2016) or
downregulated (n¼ 14, miR-24, miR-26a-5p, miR-29b, miR-30b,
miR-142-3p, miR-145, miR-194, miR-218, miR-320a, miR-375,
miR-422a, miR-423-5p, miR-601, miR-760) (Wang et al, 2012b;
Yu et al, 2013; Xu et al, 2014; Zheng et al, 2014; Basati et al, 2015;
Fang et al, 2015; Ghanbari et al, 2015; Ho et al, 2015; Ramzy et al,
2015; Li et al, 2015; Li et al, 2016) in CRC cases as compared with
controls (Table 2). Six upregulated miRNAs (miR-17-3p, miR-18a,
miR-21, miR-29a, miR-92, miR-106a) and two downregulated
miRNAs (miR-29b, miR-145) were identified by more than one
study (Ng et al, 2009; Huang et al, 2010; Kanaan et al, 2012; Wang
and Zhang, 2012; Brunet Vega et al, 2013; Liu et al, 2013; Toiyama
et al, 2013; Zhang et al, 2013; Basati et al, 2014; Du et al, 2014;
Zanutto et al, 2014; Zheng et al, 2014; Basati et al, 2015; Chen et al,
2015; Ramzy et al, 2015; Yamada et al, 2015; Li et al, 2015; Li et al,
2016). miR-21 was the most frequently identified dysregulated
miRNA (Kanaan et al, 2012; Wang and Zhang, 2012; Liu et al,
2013; Toiyama et al, 2013; Basati et al, 2014; Du et al, 2014;
Zanutto et al, 2014; Yamada et al, 2015).
Seven studies identified a two miRNA panel (Huang et al, 2010;
Wang et al, 2012b; Giraldez et al, 2013; Kanaan et al, 2013; Liu
et al, 2013; Zhang et al, 2013; Xu et al, 2014), five studies identified
a three miRNA panel (Giraldez et al, 2013; Fang et al, 2015; Ho
et al, 2015; Wang et al, 2015; Li et al, 2015), and five studies
identified a panel consisting of four or more miRNAs (Ahmed
et al, 2012; Wang et al, 2012b; Giraldez et al, 2013; Hofsli et al,
2013; Luo et al, 2013) that was utilised in the diagnosis of CRC
(Table 2).
Area under the curve, sensitivity, and specificity. The most
common method of reporting diagnostic accuracy of dysregulated
miRNAs was using AUC and sensitivity and specificity as
determined from ROC curves. Of the identified miRNAs, AUC
values ranged from 0.590 to 0.943, sensitivity ranged from 46% to
92.79% and specificity from 41% to 93.2%. The highest AUC,
sensitivity, and specificity combination was reported for a panel of
four miRNAs, miR-29a, miR-92a, miR-601, and miR-760 (AUC
0.943, sensitivity 83.3%, specificity 93.1%) (Wang et al, 2012b)
(Table 2).
Quality assessment. Quality assessment results of the studies
reporting upon single miRNA included in meta-analysis are shown
in Figures 2A and B using the QUADAS-2 evaluation tool.
Meta-analysis. Studies that identified a single dysregulated
miRNA in CRC cases compared with controls, along with the
corresponding AUC and sensitivity and specificity for the
identified miRNA, were included in the meta-analysis. Using these
criteria, 28 individual miRNAs were identified in 19 studies
(Supplementary Table S2). The sensitivity (±95% confidence
intervals (CIs)) and specificity (±95% CIs) for each miRNA are
shown in the corresponding forest plots (Figures 3A and B).
Overall sensitivity and specificity of the 28 individual miRNAs in
the diagnosis of CRC were 76% (95% CI 72–80%) and 76% (95%
CI 72–80%), respectively. These results indicate good discrimina-
tive ability of the use of miRNAs as biomarkers for the detection of
CRC. Sensitivity analyses were performed for studies of good
quality (Figures 4A and B), type of patient sample used (plasma vs
serum, Supplementary Figures S1a and b and S2a and b),
type of miRNA detection method (SYBR green vs TaqMan,
Supplementary Figures S3a and b and S4a and b), and type of
miRNA reference used for normalisation (internal vs external,
Supplementary Figures S5a and b and S6a and b). Compared with
the sensitivity and specificity obtained when including all studies,
sensitivity analysis using only high-quality studies did not
significantly alter sensitivity and specificity (77% vs 76% and
77% vs 76%, respectively). This was also true for the remaining
sensitivity analyses, where there was no improvement in sensitivity
or specificity.
DISCUSSION
This systematic review of 34 manuscripts that utilise plasma- or
serum-based miRNAs in the diagnosis of CRC has identified 617
miRNAs reported to be dysregulated in 3454 cases of CRC as
compared with 2556 healthy controls. A total of 31 single miRNAs
Table 1. ( Continued )
Study population











Ghanbari 2015 Iran 61 24 CRC 64.13±8.67 34 : 27 Plasma
Control 61.96±8.67 14 : 10
Wang S 2015 China 124 117 CRC 64 54 : 70 Plasma
Control 43 65 : 52
Wang W 2016 China 268 102 CRC 58 (49–66) 151 : 117 Serum
Control 56 (48–66) —
Sun 2016 USA 227 57 CRC 55±7.8 119 : 108 Plasma
Control 54±6.3 27 : 30
Yu J 2016 China 165 30 CRC 60.7±11.6 78 : 87 Serum
Control 59.4±14.5 15 : 15
Abbreviation: CRC, colorectal cancer.
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Table 2. Significantly dysregulated miRNAs in the plasma and serum of patients with CRC as compared with controls
miRNA Expression
Area under the
curve (AUC) Sensitivity Specificity Study
Single miRNA
miR-17-3p Upregulated 0.717 64% 70% Ng et al, 2009
0.781 —a — Li et al, 2015
miR-18a Upregulated 0.804 73.1% 79.1% Zhang et al, 2013
— — — Brunet Vega et al, 2013
miR-19a-3p Upregulated 0.849 — — Zheng et al, 2014
miR-20a Upregulated 0.590 46% 73.42% Chen et al, 2015
miR-21 Upregulated 0.910 90% 90% Kanaan et al, 2012
0.850 87.5% 74.4% Wang and Zhang, 2012
0.802 65% 85% Liu et al, 2013
0.927 82.8% 90.6% Toiyama et al, 2013
0.870 77% 78% Basati et al, 2014
0.877 76.2% 93.2% Du et al, 2014
0.647 — — Zanutto et al, 2014
miR-29a Upregulated 0.844 69% 89.1% Huang et al, 2010
— — — Brunet Vega et al, 2013
miR-92 Upregulated 0.885 89% 70% Ng et al, 2009
miR-92a 0.838 84% 71.2% Huang et al, 2010
miR-92a-3p 0.786 65.5% 82.5% Liu et al, 2013
0.890 — — Zheng et al, 2014
miR-96 Upregulated 0.740 65.4% 73.3% Sun et al, 2016
miR-106a Upregulated 0.605 74% 44.4% Chen et al, 2015
0.808 — — Li et al, 2015
miR-182 Upregulated — — — Perilli et al, 2014
miR-200c Upregulated 0.749 64.1% 73.3% Zhang et al, 2013
miR-206 Upregulated 0.705 — — Xu et al, 2014
miR-210 Upregulated 0.821 74.6% 73.5% Wang et al, 2016
miR-221 Upregulated 0.606 86% 41% Pu et al, 2010
miR-223-3p Upregulated 0.871 — — Zheng et al, 2014
miR-372 Upregulated 0.854 81.9% 73.3% Yu et al, 2016
miR-378 Upregulated 0.796 — — Zanutto et al, 2014
miR-24 Downregulated 0.839 78.38% 83.85% Fang et al, 2015
miR-26a-5p Downregulated 0.670 — — Ghanbari et al, 2015
miR-29b Downregulated 0.743 61.4% 72.5% Li et al, 2015
0.870 77% 75% Basati et al, 2015
miR-30b Downregulated — — — Ho et al, 2015
miR-142-3p Downregulated 0.710 — — Ghanbari et al, 2015
miR-145 Downregulated — — — Ramzy et al, 2015
0.874 — — Li et al, 2015
miR-194 Downregulated 0.850 72% 80% Basati et al, 2015
miR-218 Downregulated — — — Yu et al, 2013
miR-320a Downregulated 0.886 92.79% 73.08% Fang et al, 2015
miR-375 Downregulated 0.749 76.92% 64.63% Xu et al, 2014
miR-422a Downregulated 0.843 — — Zheng et al, 2014
miR-423-5p Downregulated 0.833 91.89% 70.77% Fang et al, 2015
miR-601 Downregulated 0.747 69.2% 72.4% Wang et al, 2012b
miR-760 Downregulated 0.788 80% 72.4% Wang et al, 2012b
Two miRNA panels
miR-19a, -19b Upregulated 0.820 78.57% 77.36% Giraldez et al, 2013
miR-21, -92a Upregulated 0.847 68% 91.2% Liu et al, 2013
miR-29a, -92a Upregulated 0.883 83% 84.7% Huang et al, 2010
miR-200c, -18a Upregulated 0.839 84.6% 75.6% Zhang et al, 2013
miR-431, -139-3p Upregulated 0.829 91% 57% Kanaan et al, 2013
miR-601, -760 Downregulated 0.792 83.3% 69.1% Wang et al, 2012b
miR-375, -206 Upregulated and
Downregulatedb
0.846 — — Xu et al, 2014
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were identified as significantly dysregulated between CRC cases
and controls. Eight of the dysregulated miRNAs were identified
and validated by more than one study; six were upregulated:
miR-17-3p, miR-18a, miR-21, miR-29a, miR-92, and miR-106a
and two were downregulated: miR-29b and miR-145. A further 23
significantly dysregulated miRNAs were identified by only one
Table 2. ( Continued )
miRNA Expression
Area under the
curve (AUC) Sensitivity Specificity Study
Three miRNA panels
miR-19a, -19b, -15b Upregulated 0.840 78.57% 79.25% Giraldez et al, 2013
miR-486, -25, -1180 Upregulated — — — Ho et al, 2015
miR-24, -320a, -423-5p Downregulated 0.899 92.79% 70.77% Fang et al, 2015
miR-145, -106a, -17-3p Upregulated and
Downregulated
0.886 78.5% 82.8% Li et al, 2015
miR-409-3p, -7, -93 Upregulated and
Downregulated
0.897 82% 89% Wang et al, 2015
Panels with X4 miRNA
miR-18a, -19a, -19b, -15b, 29a, -335 Upregulated 0.70–0.80 — — Giraldez et al, 2013
miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145 Upregulated 0.745 — — Luo et al, 2013
miR-423-5p, -210, -720, -320a, -378, -92a, -29a, 155 Upregulated — — — Hofsli et al, 2013
miR-7, -17-3p, -20a, -21, -92a, -96, -183, -196a, -214 Upregulated — — — Ahmed et al, 2012
miR-29a, -92a, -601, -760 — 0.943 83.3% 93.1% Wang et al, 2012b
miR-124, -127-5p, -138, -143, -146a, -222 Downregulated — — — Ahmed et al, 2012
miR-106a, -143, -103, -199-3p, -151-5p, -107, -191,
-423-3p, -221, -382, -409-3p, -652, let 7d
Downregulated — — — Hofsli et al, 2013
Abbreviations: CRC¼ colorectal cancer; miRNA¼microRNA.
aNot reported.
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Figure 2. QUADAS-2 assessment. Investigators’ assessment regarding each domain for included studies. Risk of bias and applicability concerns’
(A) graph and (B) summary.
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study. Conceptually, the increased expression of specific miRNAs
in the presence of disease is accepted, assuming that the cancer is
the source of the dysregulated miRNA export into the blood.
However, the source of the miRNA dysregulation is not necessarily
known, and miRNAs that are consistently downregulated only in
the presence of disease should not necessarily be discounted as
reliable biomarkers, provided there is an acceptable negative
predictive value for the elevated levels of that miRNA in the
absence of disease. This would, for example, be true of a miRNA
whose target was a known oncogene.
A
B
Note: Weights are from random effects analysis






















































































































































Note: Weights are from random effects analysis






















































































































































Figure 3. Forest plots for studies on individual miRNA assays used in the diagnosis of CRC among the 19 studies included in the meta-analysis.
(A) Estimates of sensitivity. (B) Estimates of specificity. A full color version of this figure is available at the British Journal of Cancer journal online.
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Significant advances have occurred in the field of tumour-
associated miRNAs since their first discovery in plasma (Mitchell
et al, 2008; Chevillet et al, 2014) as the number of studies
investigating their expression has markedly increased in
recent years. Although colonoscopy remains the gold standard
screening test for the diagnosis of CRC (Muller and Sonnenberg,
1995; Citarda et al, 2001; Zauber et al, 2012; Nishihara et al,
2013), the evaluation of miRNA within plasma and/or serum of
circulating blood has provided a new area for biomarker
research.
microRNAs are small, naturally occurring, non-protein-coding
RNA that are transcribed in the nucleus as large RNA precursors
called primary miRNAs (pri-miRNAs) (Lee et al, 2004). These pri-
miRNAs are enzymatically cleaved in the nucleus by the enzyme
Drosha into precursor miRNA (pre-miRNA) (Han et al, 2004).
The resulting approximately 70-nucleotide pre-miRNA are folded
into stem-loop structures. These pre-miRNAs are then exported
into the cytoplasm by the GTP-dependent transport protein
exportin 5 (Yi et al, 2003). Once in the cytoplasm, they undergo
additional processing by the enzyme Dicer to generate the mature
double-stranded miRNA approximately 22 nucleotides in length.
Dicer also initiates the formation of the RNA-induced silencing
complex (RISC) (Hammond, 2005). It is in this final part of
miRNA biogenesis that the leading miRNA strand is incorporated
into the RISC complex, which is then guided into the comple-
mentary 30 or 50 untranslated region of the target mRNA.
The RISC is responsible for the gene silencing observed owing to
miRNA expression and RNA interference (Filipowicz et al, 2005).
miRNAs are stable in extracellular fluid as they are protected
from RNases by virtue of being bound to argonaute proteins
(Meister, 2013). Discovery of dysregulated miRNA expression has
been identified in oesophageal, lung, liver, pancreatic, bladder,
Note: Weights are from random effects analysis
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Figure 4. Analysis performed for low-risk/low-concern studies with respect to QUADAS-2 quality assessment. (A) Quality sensitivity analysis.
Overall sensitivity was 77% (95% CI 72–83%). (B) Quality specificity analysis. Overall specificity was 77% (95% CI 72–81%). A full color version of this
figure is available at the British Journal of Cancer journal online.
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ovarian, and gastric cancers (Chiang et al, 2012). miRNAs have
been identified in numerous body fluids, such as plasma, saliva,
faeces, and urine, where they are actively released from cells within
microvesicles, exosomes, or bound to proteins (Kanaan et al, 2012;
Chevillet et al, 2014). These factors suggest that miRNAs can be
used as biomarkers for cancer and other disease states
(Turchinovich et al, 2011).
miRNAs can function as either tumour suppressors or
oncogenes. Overexpression of miRNAs in cancer may function
as oncogenes and promote oncogenesis by downregulating tumour
suppressors or other genes involved in cell differentiation. In
contrast, underexpressed miRNAs in cancer may function as
tumour suppressors by inhibiting oncogenesis via downregulation
of proteins with oncogenic qualities (Zhang et al, 2007; Shenouda
and Alahari, 2009). The miR-17-92 cluster, also known as
oncomiR-1 was the first miRNA oncogene to be described
(Li et al, 2014). Six miRNAs form this miR-17-92 cluster: miR-
17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1, and
are known to be dysregulated in many cancers (Mogilyansky and
Rigoutsos, 2013). miR-17-92 has also been found to be over-
expressed in both the tissue and serum of CRC patients (Dews
et al, 2006; Ng et al, 2009). In our systematic review, five of the six
members of this cluster, with the exception of miR-19b-1, were
found to be significantly upregulated in the serum or plasma of
CRC patients as compared with controls in eight studies (Ng et al,
2009; Huang et al, 2010; Brunet Vega et al, 2013; Liu et al, 2013;
Zhang et al, 2013; Zheng et al, 2014; Chen et al, 2015; Li et al,
2015). The most predictive miRNA was miR-92a, with AUC values
ranging from 0.786 to 0.890, from 65.5% to 89% sensitivity, and
from 70% to 82.5% specificity. The remaining member of the
cluster, miR-19b-1, was also significantly upregulated in CRC
patients when combined as a two miRNA panel together with miR-
19a, with an AUC of 0.82, 78.57% sensitivity, and 77.36%
specificity (Giraldez et al, 2013). These data support the oncogenic
role of the miR-17-92 cluster in CRC.
We identified seven different studies that demonstrated
significant upregulation of miR-21 in CRC patients as compared
with healthy controls. Kanaan et al (2012) identified miR-21 as a
biomarker for CRC. Validated CRC tissue miRNAs were evaluated
in a plasma test set consisting of 30 CRC patients and 30 healthy
controls. The most dysregulated tissue miRNAs were then
validated in different cohort of 20 CRC patients with 20 age-
and race-matched subjects without CRC. In the plasma test group,
miR-21 differentiated CRC patients from controls with AUC 0.910
and 90% specificity and sensitivity (Kanaan et al, 2012). Following
this, 6 groups reproduced similar results with AUCs ranging
from 0.647–0.927, 65–87.5% sensitivity, and 74.4–93.2% speci-
ficity. Although these data were promising, dysregulation of
miR-21 has also been described in many other cancers (Chan
et al, 2005; Iorio et al, 2005; Volinia et al, 2006; Iorio et al, 2007;
Lui et al, 2007; Meng et al, 2007; Tetzlaff et al, 2007; Hu et al,
2011). There is therefore need for a plasma miRNA profile
specific for CRC.
miR-29a is another miRNA that has been reported to be
upregulated in CRC patients in three studies (Huang et al, 2010;
Brunet Vega et al, 2013; Yamada et al, 2015). miR-29a is part of the
miR-29 family (miR-29a, miR-29b, miR-29c). Interestingly,
another member of the miR-29 family, miR-29b, was observed to
be downregulated in CRC compared with control subjects in two
studies (Basati et al, 2015; Li et al, 2016). Members of the miR-29
family exhibit differential regulation, implying that their functional
relevance may not be identical (Kriegel et al, 2012). miR-29b has
been shown to function as a tumour suppressor in various cancers
and diseases (Yan et al, 2015), while miR-29a has been shown to
act as a tumour suppressor in lung cancer (Fabbri et al, 2007) but
as an oncogene in CRC, ovarian, and breast cancer (Gebeshuber
et al, 2009; Resnick et al, 2009).
In order to reduce CRC-associated mortality, the ideal
biomarker would be able to identify individuals with both early-
stage CRC and its precursor lesion, the colorectal advanced
adenoma (CAA), from healthy control subjects. CAA have
previously been defined as adenomas with a villous component
or with high-grade dysplasia 40.75 cm size in diameter (Carter
et al, 2016b). In the studies included in this review, seven studies
evaluated miRNAs found to be significantly dysregulated in CRC
patients and in 420 patients with a diagnosis of CAA. Five of these
seven studies reported miRNA panels significantly upregulated in
CAA as compared with healthy controls (Huang et al, 2010;
Kanaan et al, 2013; Liu et al, 2013; Toiyama et al, 2013; Zheng et al,
2014). One study also identified a panel of 5 miRNAs that
distinguished between CRC and CAA with AUC 0.856 (Kanaan
et al, 2013). The remaining two studies found no significant
differences in miRNA profile between CAA and healthy controls
(Giraldez et al, 2013; Luo et al, 2013) (Supplementary Table S3).
Commercially available non-invasive screening tests have
recently been developed in an attempt to have the same detection
accuracy of CRC compared with the current gold standard
screening method of colonoscopy (2016; Imperiale et al, 2014;
Marshall et al, 2010; Nichita et al, 2014). These tests, both blood
based and faecal based, measure validated markers of CRC and
include DNA markers and gene expression profiles. To date, none
have a good ability to detect the precursor to CRC, CAA. We have
developed a plasma-based miRNA screening assay comprising of
combinations of 7 miRNAs, which is able to detect any neoplasia
from controls with AUC 0.91, colorectal neoplasia from other
cancers with AUC 0.79, and CRC from CAA with AUC 0.98. In
addition, our assay is able to differentiate CRC from controls with
AUC 0.98, sensitivity 90%, and specificity 100%, CAA from
controls with AUC 0.823, sensitivity 65%, and specificity 95%, and
CRC and CAA from controls with AUC 0.835, sensitivity 80%, and
specificity 85% (Carter et al, 2016b). This miRNA panel, although
in its infancy, provides much promise in the development of a non-
invasive screening test for detection of CRC.
Inevitably, studies included in the systematic review and meta-
analysis will vary with regards to clinical characteristics, study
design, and type of study, and these factors contribute sources of
heterogeneity. Clinical characteristics of control subjects were often
poorly defined. Of the individual studies included in the meta-
analysis, five defined healthy controls by colonoscopic confirmed
absence of CRC, including absence of adenomas. The remaining 14
studies defined healthy controls as having the absence of malignancy
or inflammatory condition or a benign physical examination without
other qualification or elaboration. Similarly, 11 studies reported no
significant differences in age or sex between CRC cases and healthy
controls, 5 reported to age-sex matching between cases and controls,
and 3 did not comment on age-sex matching status.
There was significant heterogeneity of the studies included in
this review (I2 85.7% for sensitivity, and 76.5% for specificity,
Po0.001). Heterogeneity is expected in meta-analyses, one reason
being differing sample sizes between studies (Higgins, 2008). Many
of the studies included a relatively small number of participants.
For the studies included in meta-analysis, the study populations
ranged from 32 to 268 for CRC cases and from 30 to 400 for
control cases. This may reflect the strict inclusion criteria adopted
by investigators but potentially carries the risk of type I error. In
future, studies with larger numbers of patients, along with different
populations of patients in terms of genetics, geography and
race, will increase the validity of our conclusions regarding the
reliability of plasma miRNA assays. In addition, reference miRNA
controls used varied between studies, with both internal and external
miRNAs used for normalisation of results. This may account for the
differing miRNAs identified. Similarly, miRNAs assessed were
extracted from either plasma or serum samples. Some have reported
differing miRNA concentrations depending on whether serum or
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plasma are used as the source material (Wang et al, 2012a). Unlike
previous studies, miRNAs measured in the serum of patient samples
yielded better results than for plasma in this review. Although there is
little difference in composition between plasma and serum, for
the development of a blood-based biomarker, a standard blood
component is preferred. A limitation to this review is the validity of
the results given the significant heterogeneity of the studies. We
believe it is, however, still reasonable to interpret these results as the
overwhelming majority of the studies trend towards high sensitivity
and specificity of miRNAs as biomarkers for the diagnosis of CRC.
Despite the large numbers of studies investigating plasma or
serum miRNAs in patients with CRC or CAA, there still remains
variation as to which significantly dysregulated miRNAs are
identified. Some miRNAs were found to be significantly dysregu-
lated in multiple studies, yet not all of these studies performed in
miRNA screening prior to testing and validation, for example,
miR-21, was significantly dysregulated in seven studies; however,
only one of these performed initial miRNA screening. In addition,
of the 28 miRNAs included in the meta-analysis, only 3 were
reported as significantly dysregulated by more than 1 study: miR-
21, miR-29b and miR-92.
The majority of studies were performed in either North America
or South East Asia. It is possible that genetics, geography, and race
may affect miRNA expression differently in these groups of
patients, resulting in the observed differences in significantly
dysregulated miRNAs. With the recent availability of blood-based
screening tests for CRC, it is important to focus on quality and
study reporting standards.
CONCLUSION
This systematic review identifies numerous miRNAs associated
with colorectal carcinogenesis. miRNAs can distinguish patients
with CRC from healthy controls with high sensitivity and specificity,
however; no single stand-alone miRNA has yet been identified as an
ideal biomarker for the diagnosis of CRC. In order to develop a
diagnostic test for the detection of CRC, we propose that a panel of
miRNAs with high sensitivity and specificity should be chosen and
tested in a large population of subjects. This would include a
combination of the most commonly identified miRNA, those
miRNA most predictive of CRC, and the most unique miRNA to
CRC, in order to develop a non-invasive test with sensitivity and
specificity comparable to current screening methods for CRC. In
addition, standardisation of study methodology such as the use of
serum samples, TaqMan qRT-PCR detection, and an external
miRNA reference control should be implemented in future studies.
With deaths from CRC among the leading cause of cancer
deaths worldwide, there is an emphasis to increase screening, and
therefore identify early, less invasive stage of disease, to improve
survival. For this purpose, miRNAs have the potential in the future
to be used as a relatively non-invasive, inexpensive, blood-based
marker for detection of CRC.
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